Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-08-19 , DOI: 10.1093/jac/dkaa332
Hamideh Abbaspour Kasgari ₁ , Siavash Moradi ₂ , Amir Mohammad Shabani ₁ , Farhang Babamahmoodi ₃ , Ali Reza Davoudi Badabi ₃ , Lotfollah Davoudi ₃ , Ahmad Alikhani ₃ , Akbar Hedayatizadeh Omran ₄ , Majid Saeedi ₅ , Shahin Merat ₆ , Hannah Wentzel ₇ , Anna Garratt ₈ , Jacob Levi ₉ , Bryony Simmons ₁₀ , Andrew Hill ₁₁ , Hafez Tirgar Fakheri ₁₂

Affiliation

Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran.
Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Gastrointestinal Cancer Research Center, Cancer Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Pharmaceutical Sciences Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
School of Public Health, Imperial College London, London, UK.
Cardiff and Vale University Health Board, Cardiff, UK.
Accident and Emergency Department, Homerton University Hospital NHS Trust, London, UK.
Department of Infectious Disease, Imperial College London, London, UK.
Department of Translational Medicine, University of Liverpool, UK.
Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.

中文翻译：

与标准护理相比，索磷布韦加达卡他韦联合利巴韦林治疗中度疾病住院 COVID-19 患者的疗效评估：一项单中心随机对照试验。

迫切需要新的治疗方案来应对 2019 年新型冠状病毒病 (COVID-19)。重新利用现有药物提供了立即治疗的机会。我们评估了索磷布韦和达卡他韦联合利巴韦林治疗 COVID-19 患者的疗效。

更新日期：2020-10-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11